Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the same period last year.
As of December 31, 2025, Immunovant's cash and cash equivalents totaled $994.5 million.